Biota Pharmaceuticals to Host Conference Call to Report Third Quarter Fiscal Year 2015 Financial Results

ATLANTA, April 30, 2015 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA), a biopharmaceutical company focused on the discovery and development of products to prevent and treat serious and potentially life-threatening viral respiratory infectious diseases, announced today that it will host a conference call on Thursday, May 7, 2015 at 9:00 a.m. ET to review the Company's third quarter fiscal year financial results and provide an update on recent corporate developments. The Company will issue a press release summarizing its financial results the same day, prior to the conference call.

In order to participate in the conference call, please dial (877) 312-5422 (domestic) or (253) 237-1122 (international) and refer to conference ID number 33437959. The live webcast can be accessed under the Investors section of the Company's website at www.biotapharma.com or you may use the link: http://edge.media-server.com/m/p/mqdyq7jk.

About Biota Pharmaceuticals, Inc.

Biota Pharmaceuticals, Inc. is a company focused on the discovery and development of products to treat serious viral respiratory infectious diseases. The Company currently has two clinical-stage Phase 2 product candidates: (i) laninamivir octanoate, which is being developed as a one-time treatment for influenza A and B infections; and (ii) vapendavir, a potent, broad spectrum capsid inhibitor of enteroviruses in development for the treatment of human rhinovirus infected patients with underlying respiratory illnesses, such as moderate-to-severe asthma and chronic obstructive pulmonary disease (COPD). The Company is also conducting IND-enabling studies with BTA-C585, an orally bioavailable F protein inhibitor, in development for the treatment of respiratory syncytial virus infections. For additional information about the Company, please visit www.biotapharma.com.

Biota is a registered trademark of Biota Pharmaceuticals, Inc.

CONTACT: Joseph M. Patti, PhD President and Chief Executive Officer (678) 221-3351 j.patti@biotapharma.com Sarah McCabe Stern Investor Relations, Inc. (267) 909-9237 sarah@sternir.com

Source:Biota Pharmaceuticals, Inc.